Reuters: Regulatory News: Pfizer's Lyrica does not hurt sperm in study

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Pfizer's Lyrica does not hurt sperm in study Jul 23rd 2012, 14:16 July 23 | Mon Jul 23, 2012 10:16am EDT July 23 (Reuters) - Pfizer Inc said a clinical study found its Lyrica nerve pain treatment did not affect sperm production in men taking the pill. The drugmaker conducted the study of more than 200 men as a requirement of the U.S. Food and Administration for approving Lyrica, which is one of Pfizer's biggest-selling medicines. Lyrica, also known as pregabalin, is used for diabetic nerve pain, pain after shingles and seizures for epilepsy sufferers, among other conditions. Pfizer last week won a U.S. court case protecting Lyrica's patent that stands to keep generic rivals at bay until 2018. In a separate study conducted to fulfill European requirements, Pfizer said the trial of patients with anxiety found a low number of symptoms developed after discontinuing Lyrica. Pfizer shares were off 1 percent at $23.46 in New York Stock Exchange morning trading, in a down day for the U.S. markets.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions